Christina N Cordeiro1, Mary L Gemignani2. 1. Resident Physician, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD. 2. Attending Surgeon, Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
IMPORTANCE: Cancer occurs in 0.05% to 0.1% of all pregnancies. Despite literature reporting good oncologic and fetal outcomes in women treated for cancer during pregnancy, as many as 44% of gynecologists would offer termination, and 37% would not administer chemotherapy or radiotherapy in pregnancy. OBJECTIVES: The aims of this study were to summarize current recommendations for the treatment of cervical and ovarian cancers in pregnancy and to review updates on existing knowledge regarding the safety of surgical and chemotherapeutic treatments in pregnancy, including both oncologic and fetal outcomes. EVIDENCE ACQUISITION: A detailed literature review was performed on PubMed. RESULTS: The treatment of gynecologic malignancies during pregnancy mirrors that outside pregnancy, with a balance between maternal versus fetal health. Fertility-sparing surgery can be offered to stage IA2 and low-risk IB1 cervical, stage I epithelial ovarian, germ cell ovarian, or sex-cord stromal ovarian tumors. Delayed treatment can be offered for stage IB1 cervical cancer. Neoadjuvant and/or adjuvant chemotherapy can be given for advanced gynecologic cancers with good disease-free survival without significant adverse neonatal outcomes. CONCLUSIONS: A multidisciplinary approach and improved education of providers regarding the surgical and chemotherapeutic treatments in pregnancy are needed in order to fully inform patients regarding treatment options. Further research in women who are pregnant is needed to determine the safety of diagnostic and therapeutic procedures used in the nonpregnant woman. RELEVANCE: This article reviews and supports treatment of gynecologic cancer during pregnancy, calls for additional study and long-term follow-up, and justifies improved education of patients and providers regarding treatment options. TARGET AUDIENCE: Obstetricians and gynecologists, family physicians. LEARNING OBJECTIVES: After completing this activity, the learner should be better able to (1) review general principles in the management and treatment of gynecologic cancers in pregnancy, (2) review the diagnosis and treatment of cervical cancer in pregnancy, and (3) review the diagnosis and treatment of ovarian cancer in pregnancy.
IMPORTANCE: Cancer occurs in 0.05% to 0.1% of all pregnancies. Despite literature reporting good oncologic and fetal outcomes in women treated for cancer during pregnancy, as many as 44% of gynecologists would offer termination, and 37% would not administer chemotherapy or radiotherapy in pregnancy. OBJECTIVES: The aims of this study were to summarize current recommendations for the treatment of cervical and ovarian cancers in pregnancy and to review updates on existing knowledge regarding the safety of surgical and chemotherapeutic treatments in pregnancy, including both oncologic and fetal outcomes. EVIDENCE ACQUISITION: A detailed literature review was performed on PubMed. RESULTS: The treatment of gynecologic malignancies during pregnancy mirrors that outside pregnancy, with a balance between maternal versus fetal health. Fertility-sparing surgery can be offered to stage IA2 and low-risk IB1 cervical, stage I epithelial ovarian, germ cell ovarian, or sex-cord stromal ovarian tumors. Delayed treatment can be offered for stage IB1 cervical cancer. Neoadjuvant and/or adjuvant chemotherapy can be given for advanced gynecologic cancers with good disease-free survival without significant adverse neonatal outcomes. CONCLUSIONS: A multidisciplinary approach and improved education of providers regarding the surgical and chemotherapeutic treatments in pregnancy are needed in order to fully inform patients regarding treatment options. Further research in women who are pregnant is needed to determine the safety of diagnostic and therapeutic procedures used in the nonpregnant woman. RELEVANCE: This article reviews and supports treatment of gynecologic cancer during pregnancy, calls for additional study and long-term follow-up, and justifies improved education of patients and providers regarding treatment options. TARGET AUDIENCE: Obstetricians and gynecologists, family physicians. LEARNING OBJECTIVES: After completing this activity, the learner should be better able to (1) review general principles in the management and treatment of gynecologic cancers in pregnancy, (2) review the diagnosis and treatment of cervical cancer in pregnancy, and (3) review the diagnosis and treatment of ovarian cancer in pregnancy.
Authors: Frédéric Amant; Michael J Halaska; Monica Fumagalli; Karina Dahl Steffensen; Christianne Lok; Kristel Van Calsteren; Sileny N Han; Olivier Mir; Robert Fruscio; Cathérine Uzan; Cynthia Maxwell; Jana Dekrem; Goedele Strauven; Mina Mhallem Gziri; Vesna Kesic; Paul Berveiller; Frank van den Heuvel; Petronella B Ottevanger; Ignace Vergote; Michael Lishner; Philippe Morice; Irena Nulman Journal: Int J Gynecol Cancer Date: 2014-03 Impact factor: 3.437
Authors: M Modares Gilani; M Karimi Zarchi; N Behtash; F Ghaemmaghami; A S Mousavi; F Behnamfar Journal: Int J Gynecol Cancer Date: 2007-04-12 Impact factor: 3.437
Authors: Flora Zagouri; Theodoros N Sergentanis; Dimosthenis Chrysikos; Christos A Papadimitriou; Meletios-Athanassios Dimopoulos; Rupert Bartsch Journal: Breast Cancer Res Treat Date: 2012-12-15 Impact factor: 4.872
Authors: Frédéric Amant; Gunter von Minckwitz; Sileny N Han; Marijke Bontenbal; Alistair E Ring; Jerzy Giermek; Hans Wildiers; Tanja Fehm; Sabine C Linn; Bettina Schlehe; Patrick Neven; Pieter J Westenend; Volkmar Müller; Kristel Van Calsteren; Brigitte Rack; Valentina Nekljudova; Nadia Harbeck; Michael Untch; Petronella O Witteveen; Kathrin Schwedler; Christoph Thomssen; Ben Van Calster; Sibylle Loibl Journal: J Clin Oncol Date: 2013-04-22 Impact factor: 44.544
Authors: Dai Geyang; Chen Gaowen; L I Xiaoxuan; Zheng Youhong; Wang Yuan; Li Xingsong; L I Jing; Zhou Jing; Xie Yu; Wang Yifeng Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2021-01-30
Authors: E Ulrikh; E Kalinina; E Dikareva; E Komlichenko; O Li; O Zhamborova; I Rizhinashvili; A Dzharbaeva; I Govorov; V Artemenko; V Bezrukikh; G Salogub; T Pervunina; A Urmancheeva Journal: Medicine (Baltimore) Date: 2022-07-01 Impact factor: 1.817